Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176

In this page

Clinical Trial

NCT02544217 Completed
A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176.

Phase 1
Interventional

Disease

Disease type

Leber Hereditary Optic Neuropathy (LHON)

Orphan drug recognition

NA

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

01/05/2015

Closing date

01/09/2015

Inclusion criteria :

More

Exclusion criteria :

More

Funding

industry

Members involved

Main investigators

Pr Bart LEROY

Representative

Belgium

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Others investigators

Pr Elfride DE BAERE

Substitute

Belgium

Genetic Diagnostics (TWG6), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

ERN EYE member investigating site

HCP : Principal investigators